scholarly journals Immune checkpoint blockade in renal cell carcinoma

2021 ◽  
Vol 123 (3) ◽  
pp. 739-750
Author(s):  
Phillip M. Rappold ◽  
Andrew W. Silagy ◽  
Ritesh R. Kotecha ◽  
Ari A. Hakimi
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

scholarly journals SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients

Aging ◽  
2020 ◽  
Vol 12 (19) ◽  
pp. 19316-19324
Author(s):  
Pengju Li ◽  
Jeifei Xiao ◽  
Bangfen Zhou ◽  
Jinhuan Wei ◽  
Junhang Luo ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Clear Cell ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Cell Renal Cell Carcinoma

scholarly journals Nivolumab and Ipilimumab Immunotherapy for Hemodialysis Patients with Advanced Renal Cell Carcinoma

2020 ◽  
Vol 27 (4) ◽  
pp. 225-228
Author(s):  
Y. Kobayashi ◽  
H. Arai ◽  
M. Honda
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Function ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Advanced Renal Cell Carcinoma ◽  
Safety And Efficacy

Combined immune checkpoint blockade with nivolumab and ipilimumab is standard therapy for the treatment of patients with previously untreated advanced renal cell carcinoma who are at intermediate or poor risk. However, data about the safety and efficacy of combined immune checkpoint blockade with nivolumab and ipilimumab in patients on hemodialysis are limited. Renal function has no known clinically important effects on the pharmacokinetics and clearance of nivolumab and ipilimumab. Further, most immune-related adverse events in patients on hemodialysis are thought to be manageable with the same treatments applied in patients with normal renal function. We present a case of advanced clear-cell renal cell carcinoma in a patient on hemodialysis who received combined immune checkpoint blockade with nivolumab and ipilimumab and who showed no evident signs of immune-related adverse events. Here, we confirm the safety and efficacy of combined immune checkpoint blockade with nivolumab and ipilimumab in a patient on hemodialysis.

scholarly journals Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era

2021 ◽  
pp. 1-11
Author(s):  
Andrew L. Schmidt ◽  
Alexandra L. Tabakin ◽  
Eric A. Singer ◽  
Toni K. Choueiri ◽  
Rana R. McKay
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Systemic Therapy ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Multidisciplinary Care ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Treatment Naïve

Systemic therapy for first-line metastatic renal cell carcinoma has evolved toward immune checkpoint blockade combinations incorporating a PD-1/L1 inhibitor along with CTLA-4 inhibition or VEGF-targeted therapy. The new treatment paradigm that integrates immunotherapy for treatment-naïve advanced metastatic renal cell carcinoma creates a new therapeutic challenge for clinicians including the optimal way to integrate multidisciplinary care involving surgery, radiotherapy, and application of contemporaneous systemic treatment in subsequent lines of therapy following discontinuation of combination therapy. We outline the available data for the multidisciplinary management of metastatic renal cell carcinoma, systemic therapy options in the post–immune checkpoint blockade setting, and novel therapies in development for advanced renal cell carcinoma. We provide practical considerations to assist clinicians in treatment choice and map future directions for progress.

Sign in / Sign up

Export Citation Format

Share Document